PCRX
$36.38+0.11%
Pacira BioSciences Inc.Stock · HealthcareRussell 2000 · 0.03% of IWMRussell 3000 · 0.002% of IWVUS Stock Market · 0.001% of VTI
PCRX financial statements
The full income statement, balance sheet, and cash-flow statement for Pacira BioSciences Inc. (PCRX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 46.1M2024-09 46.2M2024-12 46.3M2025-03 46.3M2025-06 44.9M2025-09 43.0M2025-12 40.5M2026-03 39.3M2026-06 39.9M-13.6% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
PeriodRangeOrderChangeFiguresAs-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 726M+3.6% | 701M+3.9% | 675M+1.2% | 667M+23.1% | 542M+26.0% | |
| Cost of revenue | 150M-12.1% | 170M-7.7% | 185M-7.3% | 199M+42.1% | 140M+19.5% | |
| Research & development | 117M+43.8% | 81.6M+7.0% | 76.3M-10.1% | 84.8M+52.7% | 55.5M-6.5% | |
| Selling, general & administrative | 369M+25.4% | 294M+9.2% | 269M+5.9% | 255M+27.7% | 199M+3.0% | |
| Restructuring | 3.67M-56.9% | 8.53M+669.3% | 1.11M | 0.00 | 0.00+100.0% | |
| Amortization of intangibles | 57.3M+0.0% | 57.3M+0.0% | 57.3M+0.0% | 57.3M+322.7% | 13.6M+72.3% | |
| Operating income | 19.2M+126.2% | -73.4M-183.7% | 87.7M+46.1% | 60.0M-33.3% | 89.9M+94.0% | |
| Interest expense | 17.4M+5.3% | 16.6M-18.4% | 20.3M-49.2% | 40.0M+25.9% | 31.8M+23.7% | |
| Interest & investment income | 22.7M+15.5% | 19.7M+72.0% | 11.4M+152.0% | 4.54M+406.9% | 896K-80.6% | |
| Other non-operating income | -6.62M-1674.8% | -373K-100.5% | -186K+98.4% | -11.3M-323.4% | -2.67M-193.5% | |
| Pre-tax income | 16.9M+126.7% | -63.1M-202.3% | 61.7M+363.8% | 13.3M-76.4% | 56.4M+180.8% | |
| Income tax | 9.84M-73.0% | 36.5M+84.6% | 19.7M+857.4% | -2.61M-118.1% | 14.4M+111.5% | |
| Net income | 7.03M+107.1% | -99.6M-337.3% | 42.0M+163.7% | 15.9M-62.1% | 42.0M-71.2% | |
| $0.16+107.4% | -$2.15-341.6% | $0.89+161.8% | $0.34-63.0% | $0.92-72.4% | ||
| EPS (basic) | $0.16+107.4% | -$2.15-336.3% | $0.91+160.0% | $0.35-63.2% | $0.95-72.1% | |
| Weighted-avg shares (basic) | 44.6M-3.6% | 46.2M+0.0% | 46.2M+1.5% | 45.5M+2.8% | 44.3M+3.7% | |
| Weighted-avg shares (diluted) | 45.0M-2.6% | 46.2M-11.0% | 52.0M+11.7% | 46.5M+2.0% | 45.6M+4.5% | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 548M-26.5% | 745M+46.1% | 510M+2.3% | 498M-42.5% | 866M+32.9% | ||
| Cash & equivalents | 159M-42.7% | 277M+80.5% | 153M+47.2% | 104M-82.2% | 586M+485.8% | |
| Short-term investments | 79.9M-61.6% | 208M+65.9% | 125M-32.1% | 185M+160.5% | 70.8M-83.2% | |
| Accounts receivable | 124M+9.5% | 113M+7.3% | 106M+7.3% | 98.4M+2.2% | 96.3M+81.6% | |
| Inventory | 153M+22.0% | 125M+20.1% | 104M+8.6% | 96.1M-2.5% | 98.5M+52.4% | |
| Prepaid expenses | 32.6M+48.7% | 21.9M+2.0% | 21.5M+41.3% | 15.2M+3.1% | 14.8M+20.4% | |
| 1.26B-18.6% | 1.55B-1.3% | 1.57B-6.4% | 1.68B-19.0% | 2.08B+62.8% | ||
| Property, plant & equipment | 141M-15.8% | 167M-3.9% | 174M-5.2% | 184M-2.6% | 188M+37.8% | |
| Operating lease right-of-use | 41.8M-15.1% | 49.2M-19.3% | 61.0M-13.9% | 70.9M-7.2% | 76.4M+2.6% | |
| Goodwill | 20.2M | 0.00-100.0% | 163M+0.0% | 163M+12.4% | 145M+45.9% | |
| Intangible assets | 368M-13.6% | 426M-11.9% | 483M-10.6% | 541M-13.4% | 624M+546.5% | |
| Long-term investments | — | 0.00-100.0% | 2.41M-93.5% | 37.2M | 0.00-100.0% | |
| Deferred tax assets | 124M-5.0% | 130M-9.8% | 144M-9.9% | 160M+4.5% | 153M+44.5% | |
| 121M-61.1% | 310M+218.2% | 97.4M-34.1% | 148M-71.6% | 521M+105.7% | ||
| Accounts payable | 15.2M-20.8% | 19.1M+21.9% | 15.7M+3.1% | 15.2M+44.4% | 10.5M+1.1% | |
| Accrued liabilities | 95.6M+19.3% | 80.1M+24.7% | 64.2M-28.4% | 89.8M-29.6% | 128M+79.7% | |
| Short-term & current debt | 0.00-100.0% | 202M | — | — | — | |
| Current lease liability | 9.84M+10.7% | 8.89M+1.0% | 8.80M-3.5% | 9.12M+15.6% | 7.89M+6.3% | |
| 572M-26.2% | 775M+10.1% | 704M-22.3% | 906M-32.6% | 1.34B+105.4% | ||
| Long-term debt | 372M-3.0% | 384M-26.6% | 522M-24.2% | 689M | — | |
| Deferred revenue (non-current) | — | — | — | — | 10.1M | |
| Non-current lease liability | 36.2M-19.0% | 44.6M-18.5% | 54.8M-15.4% | 64.8M-9.7% | 71.7M+1.0% | |
| Operating lease liability (total) | 46.0M-14.0% | 53.5M-15.8% | 63.6M-14.0% | 73.9M-7.2% | 79.6M+1.5% | |
| Deferred tax liabilities | 4.21M | 0.00 | — | — | — | |
| Other non-current liabilities | 20.6M+22.3% | 16.8M+23.9% | 13.6M+40.4% | 9.67M-51.6% | 20.0M+421.2% | |
| 693M-11.0% | 778M-10.5% | 870M+12.3% | 775M+6.1% | 730M+17.9% | ||
| Preferred stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock | 48.0K+2.1% | 47.0K+2.2% | 46.0K+0.0% | 46.0K+2.2% | 45.0K+2.3% | |
| Additional paid-in capital | 1.06B+5.5% | 1.01B+3.4% | 977M+5.7% | 924M-1.9% | 942M+7.9% | |
| Retained earnings | -199M+3.4% | -206M-93.2% | -107M+28.2% | -149M+29.8% | -212M+16.5% | |
| Treasury stock | 177M+602.9% | 25.1M | 0.00 | — | — | |
| Accumulated other comprehensive income | 4.33M+1161.5% | 343K+38.9% | 247K+165.0% | -380K-327.5% | 167K-47.5% | |
| Total liabilities & equity | 1.26B-18.6% | 1.55B-1.3% | 1.57B-6.4% | 1.68B-19.0% | 2.08B+62.8% | |
| Common shares issued | 47.9M+1.7% | 47.1M+1.3% | 46.5M+1.2% | 45.9M+2.7% | 44.7M+2.5% | |
| Common shares outstanding | 41.1M-11.1% | 46.2M-0.5% | 46.5M+1.2% | 45.9M+2.7% | 44.7M+2.5% | |
| Shares outstanding (cover) | 40.5M-12.5% | 46.3M-0.5% | 46.5M+1.2% | 46.0M+2.5% | 44.8M+2.2% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 152M-19.7% | 189M+22.5% | 155M+6.5% | 145M+15.6% | 126M+63.2% | ||
| Depreciation & amortization | 91.0M+15.5% | 78.8M+4.2% | 75.6M-17.4% | 91.5M+220.5% | 28.5M+43.4% | |
| Intangible amortization | 57.3M+0.0% | 57.3M+0.0% | 57.3M+0.0% | 57.3M+322.7% | 13.6M+72.3% | |
| Share-based compensation | 57.5M+12.4% | 51.2M+6.8% | 47.9M-0.4% | 48.1M+13.8% | 42.2M+5.8% | |
| Deferred income taxes | 6.48M-68.6% | 20.6M+32.1% | 15.6M+296.5% | -7.95M-173.1% | 10.9M+108.6% | |
| Change in receivables | 10.7M+38.6% | 7.75M+8.2% | 7.16M+244.3% | 2.08M-80.1% | 10.4M+89.2% | |
| Change in inventory | 27.6M+31.7% | 20.9M+152.5% | 8.29M+433.5% | -2.49M-155.7% | 4.47M-29.7% | |
| Change in payables | -5.60M-281.5% | 3.08M+236.7% | 916K-85.4% | 6.27M+161.1% | -10.3M-209.8% | |
| Other operating activities | — | — | — | 92.0K-96.6% | 2.67M+265.2% | |
| 99.5M+219.5% | -83.3M-207.4% | 77.5M+134.4% | -225M-983.1% | -20.8M+92.5% | ||
| Capital expenditure | 15.3M+44.2% | 10.6M-29.8% | 15.2M-49.6% | 30.1M-34.4% | 45.9M+21.3% | |
| Free cash flow | 137M-23.5% | 179M+28.1% | 139M+21.1% | 115M+44.3% | 79.9M+103.5% | |
| Acquisitions | 16.7M | 0.00 | 0.00 | 0.00-100.0% | 420M | |
| -370M-2228.8% | 17.4M+109.5% | -183M+54.4% | -402M-205.5% | 381M+71.2% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock repurchased | 148M+493.3% | 25.0M | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FX effect on cash | -77.0K | 0.00 | 0.00 | — | — | |
| Net change in cash | -118M-195.8% | 123M+151.2% | 49.2M+110.2% | -481M-199.1% | 486M+2134.9% | |
| Interest paid | 15.2M-1.2% | 15.4M-44.2% | 27.6M-17.0% | 33.3M+375.9% | 7.00M-2.9% | |
| Income taxes paid | 9.01M-18.1% | 11.0M+150.0% | 4.40M-40.5% | 7.40M+129.7% | 3.22M+33.3% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 1.05B+20.2% | 872M-44.4% | 1.57B-11.6% | 1.77B-34.4% | 2.70B+2.8% | |
| P/E | 149.0× | — | 224.4×+164.5% | 84.8×+32.0% | 64.3×+256.4% | |
| P/S | 1.4×+16.0% | 1.2×-47.2% | 2.4×-13.1% | 2.7×-45.6% | 5.0×-18.4% | |
| P/B | 1.5×+35.0% | 1.1×-40.6% | 1.9×-18.1% | 2.3×-37.7% | 3.7×-12.8% | |
| P/FCF | 7.7×+57.2% | 4.9×-59.5% | 12.0×-37.1% | 19.1×-43.5% | 33.8×-49.5% | |
| Earnings yield | 0.67% | — | 0.45%-62.2% | 1.2%-24.2% | 1.6%-71.9% | |
| FCF yield | 13.0%-36.4% | 20.5%+146.6% | 8.3%+58.9% | 5.2%+76.8% | 3.0%+98.0% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: PCRX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all PCRX filings on SEC EDGAR → Not investment advice.